If you have been reading about melanogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Trump's administration strained relations with South Africa. Trump suspended all aid to South Africa, saying the country's land expropriation law discriminated against Afrikaners; he also offered Afrikaners refugee status in the U.S. Rubio refused to attend the G20 foreign ministers' meeting in Johannesburg and he declared the South African ambassador persona non grata for his criticism of U.S. policies.
In October 2025, GSK announced it had acquired the rights to a prostate cancer drug developed by Syndivia, a French biotechnology company, for £268 million. In January 2026, GSK agreed to acquire Rapt Therapeutics in a deal valued at $2.2 billion. In January 2026, Alteogen Inc. entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK, allowing Tesaro to acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilising Hybrozyme technology, for the development and commercialisation of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. In February 2026, GlaxoSmithKline announced an agreement to acquire Canada-based biopharmaceutical firm 35Pharma for $950 million in cash. The deal includes the early-stage drug HS235 for pulmonary arterial hypertension and related conditions. In June 2026, GSK announced it was acquiring Nuvalent, an American biopharmaceutical company, for $10.6 billion. Subject to regulatory and shareholder approval, if complete, the deal will be its largest in more than 10 years.
Neither the patient nor the healthcare provider knew which treatment was being given until after the trials. Treatment was given for 40 weeks. In the other three trials (NCT3987919, NCT03882970, and NCT03730662), participants were randomly assigned to receive either tirzepatide or another antidiabetic medication, and both the patient and the provider knew which medication was being given. Treatment was given for 40 weeks to 104 weeks. In each trial, HbA1c was measured from the start to the end of the trial and compared between the tirzepatide group and the other groups. Tirzepatide's efficacy for chronic weight management (weight reduction and maintenance) in combination with a reduced-calorie diet and increased physical activity was established in two randomized, double-blind, placebo-controlled trials in adults with obesity or overweight who had at least one weight-related condition. These studies measured weight reduction after 72 weeks in 2,519 participants who received either 5, 10, or 15 mg of tirzepatide once weekly and 958 participants who received weekly placebo injections. In both trials, after 72 weeks of treatment, participants who received tirzepatide at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of participants who received tirzepatide achieved at least 5% weight reduction compared to placebo.
Sources: en.wikipedia.org
=== Lifestyle === Exclusive breastfeeding is recommended in all newborn infants for its nutritional and other beneficial effects. Parents changing the diet and lifestyle of their offspring by offering appropriate food portions, increasing physical activity, and keeping sedentary behaviors at a minimum may also decrease the obesity levels in children. Promoting more physical activity can help prevent and manage obesity. Walking or riding a bike, instead of using motorised transport or watching television, will reduce sedentary activity.
== Signs and symptoms == ALD can present in different ways. The different presentations are complicated by the pattern of X-linked recessive inheritance. There have been seven phenotypes described in males with ABCD1 mutations and five in females. Initial symptoms in boys affected with the childhood cerebral form of ALD include emotional instability, hyperactivity and disruptive behavior at school. Older patients affected with the cerebral form will present with similar symptoms. Untreated, cerebral ALD is characterized by progressive demyelination leading to a vegetative state and death. Adult males with an adrenomyeloneuropathy presentation typically present initially with muscle stiffness, paraparesis and sexual dysfunction. All patients with clinically recognized ALD phenotypes are at risk for adrenal insufficiency. There is no reliable way to predict which form of the disease an affected individual will develop, with multiple phenotypes being demonstrated within families. Onset of adrenal insufficiency is often the first symptom, appearing as early as two years of age.
Ada Esther Yonath (Hebrew: עדה יונת, pronounced [ˈada joˈnat]; née Lifshitz; 22 June 1939 – 31 August 2026) was an Israeli crystallographer and Nobel laureate in chemistry, best known for her pioneering work on the structure of ribosomes. She was the director of the Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly of the Weizmann Institute of Science. In 2009, Yonath received the Nobel Prize in Chemistry along with Venkatraman Ramakrishnan and Thomas A. Steitz for her studies on the structure and function of the ribosome, becoming the first Israeli woman to win the Nobel Prize.
Sources: en.wikipedia.org
== External links == glycosciences.de This site provides databases and bioinformatics tools for glycobiology and glycomics. GlycomeDB, A carbohydrate structure metadatabase GlycoBase A web HPLC/UPLC resource that contains elution positions expressed as glucose unit values. ProGlycAn A short introduction to glycan analysis and a nomenclature for N-Glycans Emanual Maverakis; et al. "Glycans in the immune system and The Altered Glycan Theory of Autoimmunity" (PDF). CD BioGlyco This site provides database and tools in the field of glycomics, from glycan release, separation, and purification, glycan derivatization to glycan characterization and quantification.
Other families claimed that their loved ones did not have any problems with anybody and were honest workers. Nevertheless, when the cartel members arrested were interrogated by the authorities, they claimed that those killed in the massacre were not innocent, and formed part of Los Torcidos (another name for the Jalisco New Generation Cartel). When asked if they had tortured them, the cartel members replied that they did not. One of the killers confessed that he had plans of leaving the criminal organization but was threatened with death by his own organization if he decided to do so. Authorities concluded that this massacre was almost a "replica" of what happened two months earlier in Veracruz, and investigators mentioned that this massacre is a response to the killings done by the Matazetas against Los Zetas in the state of Veracruz.
Recently, a new technique called NeuCode SILAC, has augmented the level of multiplexing achievable with metabolic labeling (up to 4). The NeuCode amino acid method is similar to SILAC but differs in that the labeling only utilizes heavy amino acids. The use of only heavy amino acids eliminates the need for 100% incorporation of amino acids needed for SILAC. The increased multiplexing capability of NeuCode amino acids is from the use of mass defects from extra neutrons in the stable isotopes. These small mass differences however need to be resolved on high resolution mass spectrometers. One of the main benefits of SILAC is the level of quantitation bias from processing errors is low because heavy and light samples are combined before sample preparation for MS analysis. SILAC and NeuCode SILAC are excellent techniques for detecting small changes in protein levels or post-translational modifications between experimental groups.
== Inter-connectivity == To create a fast logistics gateway for national and international trade, the expressway will connect the country's largest container port, JNPT in Mumbai to Mihan in Nagpur. The expressway will allow access to several industrial and economic corridors through 24 interchanges at strategic locations. It will widely connect the Delhi–Mumbai Industrial Corridor, Bengaluru–Chennai Economic Corridor, Western Dedicated Freight Corridor, Eastern Dedicated Freight Corridor, Chennai–Vizag Economic Corridor, and Golden Quadrilateral. Apart from JNPT, other seaports including Kandla MBPT, Mormugao, New Mangalore, Kochi, Chennai, Visakhapatnam and Ennore will also have indirect connectivity. The Samruddhi Mahamarg connects 15–16 districts directly to Jawaharlal Nehru Port Trust (JNPT), reducing cargo delivery times from six to seven days to under ten hours, supporting Maharashtra's port-led growth strategy. The following will either connect or act as an alternative to the Mumbai–Nagpur Expressway:
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.